- Home
- IBRX vs MSGE Comparison
IBRX vs MSGE Comparison
Compare IBRX & MSGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBRX
- MSGE
- Stock Information
- Founded
- IBRX 2014
- MSGE 2020
- Country
- IBRX United States
- MSGE United States
- Employees
- IBRX N/A
- MSGE N/A
- Industry
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- MSGE Services-Misc. Amusement & Recreation
- Sector
- IBRX Health Care
- MSGE Consumer Discretionary
- Exchange
- IBRX Nasdaq
- MSGE Nasdaq
- Market Cap
- IBRX 2.3B
- MSGE 1.9B
- IPO Year
- IBRX N/A
- MSGE N/A
- Fundamental
- Price
- IBRX $2.76
- MSGE $44.91
- Analyst Decision
- IBRX Strong Buy
- MSGE Strong Buy
- Analyst Count
- IBRX 6
- MSGE 5
- Target Price
- IBRX $9.83
- MSGE $50.20
- AVG Volume (30 Days)
- IBRX 9.7M
- MSGE 370.1K
- Earning Date
- IBRX 11-11-2025
- MSGE 11-07-2025
- Dividend Yield
- IBRX N/A
- MSGE N/A
- EPS Growth
- IBRX N/A
- MSGE N/A
- EPS
- IBRX N/A
- MSGE 0.77
- Revenue
- IBRX $56,600,000.00
- MSGE $942,734,000.00
- Revenue This Year
- IBRX $629.94
- MSGE $8.41
- Revenue Next Year
- IBRX $109.91
- MSGE $4.79
- P/E Ratio
- IBRX N/A
- MSGE $58.44
- Revenue Growth
- IBRX 4227.22
- MSGE N/A
- 52 Week Low
- IBRX $1.83
- MSGE $28.29
- 52 Week High
- IBRX $7.48
- MSGE $45.53
- Technical
- Relative Strength Index (RSI)
- IBRX 64.62
- MSGE 73.09
- Support Level
- IBRX $2.32
- MSGE $43.06
- Resistance Level
- IBRX $2.67
- MSGE $40.92
- Average True Range (ATR)
- IBRX 0.14
- MSGE 1.09
- MACD
- IBRX 0.05
- MSGE 0.43
- Stochastic Oscillator
- IBRX 72.73
- MSGE 89.61
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
About MSGE Madison Square Garden Entertainment Corp.
Madison Square Garden Entertainment Corp provides live entertainment, delivering unforgettable experiences while forging deep connections with diverse and passionate audiences. The company's portfolio includes a collection of world-renowned venues - New York's Madison Square Garden, The Theater at Madison Square Garden, Radio City Music Hall, and Beacon Theatre; and The Chicago Theatre - that showcase a broad array of sporting events, concerts, family shows, and special events for millions of guests annually. In addition, the company features the original production, the Christmas Spectacular Starring the Radio City Rockettes, which has been a holiday tradition for 89 years.